for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tiziana Life Sciences Ltd - ADR

TLSA.O

Latest Trade

1.32USD

Change

0.01(+0.76%)

Volume

42,742

Today's Range

1.24

 - 

1.35

52 Week Range

1.18

 - 

5.29

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.31
Open
1.33
Volume
42,742
3M AVG Volume
8.45
Today's High
1.35
Today's Low
1.24
52 Week High
5.29
52 Week Low
1.18
Shares Out (MIL)
194.61
Market Cap (MIL)
25.73
Forward P/E
-9.60
Dividend (Yield %)
--

Next Event

Full Year 2021 Tiziana Life Sciences PLC Earnings Release

About Tiziana Life Sciences Ltd - ADR

Tiziana Life Sciences Ltd is a clinical stage biotechnology company. The Company is focused on the discovery and development of molecules and related diagnostics to treat unmet medical needs in oncology and immunology. Its lead product candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501), and Milciclib TZLS-201. Foralumab (TZLS-401) is a fully human engineered anti-human cluster of differentiation 3 (CD3) monoclonal antibody (mAb). Foralumab is developed for the treatment of neurodegenerative diseases such as progressive Multiple Sclerosis (MS), and Crohn’s disease. The Anti IL-6R mAb (TZLS-501) is a fully human engineered mAb targeting the interleukin-6 receptor (IL-6R). Anti-IL-6R antibody can be used in combination with Foralumab or other anti-inflammatory and anti-infective agents as therapy for COVID-19 and oncology indications. The Company has developed Milciclib TZLS-201 for the treatment of hepatocellular carcinoma (HCC).

Industry

Business Services

Contact Info

Executive Leadership

Gabriele M.A. Cerrone

Executive Chairman of the Board

Shailubhai Kunwar

Chief Executive Officer, Chief Scientific Officer, Director

Thomas H. Adams

Executive Director

Neil Graham

Chief Medical Officer

John P. Brancaccio

Non-Executive Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.122

2019

-0.028

2020

-0.181

2021(E)

-0.127
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.46
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.35
LT Debt To Equity (MRQ)
0.86
Return on Investment (TTM)
-142.01
Return on Equity (TTM)
-110.65

Latest News

Latest News

GLOBAL MARKETS-Stocks stalled as oil fuels inflation nerves

* Asia stocks dip on China debt jitters, S&P 500 futures -0.4%

GLOBAL MARKETS-Stocks stalled as oil fuels inflation nerves

Asian stockmarkets were becalmed on Wednesday as surges in oil and Chinese factory prices added to worries that a hot U.S. inflation reading could renew pressure on policymakers to lift interest rates.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up